Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Unknown 9Recruiting 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 49INDUSTRY 4NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Solid Tumors 1Multiple Myeloma 1Glioma 1Gastric Adenocarcinoma 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Immunotherapy, Adoptive × Clear all
NCT06482905 2026-03-24

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Tcelltech Inc.

Phase 1 Recruiting
52 enrolled
CNS

Glioma

NCT07231081 2025-11-17

Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

Tcelltech Inc.

Phase 1 Recruiting
85 enrolled
Other solid neoplasm

Solid Tumors

NCT07103668 2025-10-23

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Suzhou Immunofoco Biotechnology Co., Ltd

Phase 3 Recruiting
150 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT05521802 2023-03-24

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Shanghai AbelZeta Ltd.

Phase 1/2 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡